Roche's head of pharmaceuticals to leave company

  • 📰 Reuters
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 97%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Roche said on Monday the head of its pharmaceuticals division had decided to leave after 16 years with the Swiss drugmaker, heralding a wider reshuffle in addition to a planned CEO changeover early next year.

The Swiss company's shares have dropped about 20% so far this year, a worse performance than the 5% decline in the STOXX Europe 600 Health CareSchinecker will replace Severin Schwan, who is slated to become chairman after 14 years as CEO of Roche.

"Over his 16-year career at Roche, Bill Anderson has demonstrated excellent leadership. He has been instrumental in shaping Roche's transformation and I wish him all the best for the future," Schwan said in a statement. Anderson joined California-based Genentech in 2006 as senior vice president of the Immunology and Ophthalmology Business Unit, before leading the Bio oncology Business Unit.In proposals for next year's AGM, Roche also confirmed its intention to propose Schwan as the next chairman.

As previously announced in July 2022, Christoph Franz has decided not to seek re-election as chairman, Roche said on Monday.CEO Mark Schneider and Akiko Iwasaki, an Immunobiology professor at Yale University, would stand for election as new board members at next year's annual general meeting.Our Standards:

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

mcuban

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 2. in BR

Brasil Últimas Notícias, Brasil Manchetes